Case report: Long-term survival in patients with initial lung-only metastasis from pancreatic adenocarcinoma

Journal of Gastrointestinal Cancer

Volumn 43, Issue SUPPL. 1, 2012, Pages

  Gotfried, Jonathan I ^a,b,c   Kozuch, Peter S ^a,b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Institute for Head and Neck and Thyroid Cancer   (United States)

^c TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAPECITABINE PLUS OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CONTINUOUS INFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LUNG METASTASIS; MALE; MEDICAL RECORD REVIEW; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; WEDGE RESECTION; ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; DISEASE COURSE; LUNG PARENCHYMA; MULTIPLE CYCLE TREATMENT;

ADENOCARCINOMA; ADULT; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PNEUMONECTOMY; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84871211397     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9304-y     Document Type: Article

References (57)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty. Oncologist. 2008;13(5):562-76.
3. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007;18 Suppl 7:vii1-vii10.
4. Turaga K, Kaushik M, Forse RA, Sasson AR. In hospital outcomes after pancreatectomies: an analysis of a national database from 1996 to 2004. J Surg Oncol. 2008;98:156-60.
5. Chang Baochong B, Thomas Melanie B, A.Wolff Robert, "Chapter 15. Pancreatic Cancer and Hepatobiliary Malignancies" (Chapter). Kantarjian HM, Wolff RA, Koller CA: MD Anderson Manual of Medical Oncology: http://www.accessmedicine.com/content.aspx?aID=2789739.
6. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106 (7):1624-33.
7. Merl MY, Abdelghany O, Li Jia, Saif MW. First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? J Pancreas (Online). 2010;11(4):317-20.
8. Cubiella J, Castells A, Fondevila C, Sans M, Sabater L, Navarro S, et al. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol. 1999;94:1271-8.
9. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-22.
10. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results from over 3000 patients with pancreatic carcinoma. Cancer. 1999;85(6):1261-8.
11. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001;24:547-50.
12. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology. 2000;59:296-301.
13. Van Cutsem E, van de Velde H, Harasek P, Oettle H, VervenneWL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-8.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual, 5th Printing. 7th ed. New York, NY: Springer; 2010.
15. Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009;100(12):1842-5.
16. Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, et al. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2009;64(2):317-25.
17. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. [Erratum appears in Cancer Chemother Pharmacol 2008 Jan;61(1):177]. Cancer Chemother Pharmacol. 2008;61 (1):167-75.
18. Takahashi Y, Mai M, Sawabu N, Nishioka K. A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas. 2005;30(3):206-10.
19. Giuseppe C, Labianca R, Di Costanzo F, Gebbia V, Cateni G, Masssidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. Journal of Clinical Oncology. 2010;28(10):1645-51.
20. Philip PA, Benedetti J, Corless CL, Corless CL, Wong R, O'Reilly EM, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605-10.
21. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137:361-71.
22. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679-95.
23. Hess KR, Varadhachary GR, Taylor SH, Wei Wei MS, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624-33.
24. Casciato DA, Territo MC. Manual of clinical oncology. Sixthth ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009. p. 3-18.
25. Van Meerbeeck JP, Gosselin R, Duyck Ph. Lung metastases: epidemiology, clinical presentation, and imaging. 1st ed. New York, NY: Nova Science Publishers, Inc; 2005. p. 3-26.
26. Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11(4):345-9.
27. Tan KK, de Lima Lopes G, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg. 2009;13:642-8.
28. Lisa JR, Trinidad S, Rosenblatt MB. Pulmonary manifestations of carcinoma of the pancreas. Cancer. 1964;17:395-401.
29. Mao C, Domenico DR, Kim K, Hanson DJ, Howard JM. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma: findings of 154 autopsies. Arch Surg. 1995;130:125-34.
30. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther. 2005;4:548-54.
31. Merrie AE, Phillips LV, Yun K, McCall JL. Skip metastases in colon cancer: assessment by lymph node mapping using molecular detection. Surgery. 2001;129(6):684-91. doi:10.1067/msy.2001.113887.
32. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Molecular Cancer. 2003;2:14.
33. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814-23.
34. Saur D, Seidler B, Schneider G, Algul H, Beck R, Senekowitsch-Schmidtke R, et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology. 2005;129:1237-50.
35. Wang P, Chen Z, Meng Z, Fan J, Luo JM, LiangW, et al. Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasissuppressive function. Carcinogenesis. 2009;30:1497-506.
36. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009;69:5364-73.
37. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518-24.
38. van Deventer HW, O'Connor Jr W, Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res. 2005;65:3374-9.
39. Brown DM, Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediate lung metastasis. Cancer Cell. 2004;5:365-74.
40. Hirtsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2(4):289-300.
41. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, et al. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol. 2009;2:13.
42. Hezel AF, Bardeesy N. Prognostic markers in pancreatic ductal adenocarcinomas. Cancer Biol Ther. 2008;7(9):1360-1.
43. Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, et al. Long-term survival (5-20 Years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from3 institutions. Pancreas. 2008;37(4):352-7.
44. Silberstein E, Walfisch S, Lupu L, Sztarkier I. Twelve-year survival after the diagnosis of locally advanced carcinoma of the pancreas: a case report. J Surg Oncol. 2000;75:142-5.
45. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, et al. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP. 2006;7:486-91.
46. Yeh JJ. Prognostic signature for pancreatic cancer: are we close? Future Oncol. 2009;5:313-21.
47. Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol. 2007;13:224-7.
48. Saad ED, Machado M, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32:35-41.
49. Pérez-Gracia JL, Gúrpide A, Ruiz-Ilundain MG, Alegría CA, García-Foncillas RCJ, Bermejo IM. Selection of extreme phenotypes: the role of clinical observation in translational research. Clin Transl Oncol. 2010;12(3):174-80.
50. Katyal S, Oliver JH, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216:698-703.
51. Kojima Y. Hepatocellular carcinoma presenting with lung metastasis: clinical characteristics and prognostic factors. J Clin Oncol. 2009;27(15s):e15604.
52. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13(3):414-20.
53. D' Angelica, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh M. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808-16.
54. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383-8.
55. Weiss L, Grundmann E, Torhorst J. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsis. J Path. 1986;150(3):195-203.
56. D'Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. The impact of recurrence patterns after hepatectomy for colorectal metastases on outcome. Annals of Surgical Oncology (in press)
57. Kobayashi H, Mochizuki H, Sugihara K, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007;141:67-75.